var eventsData = [{"Ticker":"IVZ","EffectiveDate":"2017-01-26","Type":"EarningsRevenueBeat","Title":"Before market open, IVZ reports 2016 Q4's earning $0.59 per share and revenue $863.8MM. This beats analyst's estimated EPS $0.58, beats estimated revenue $862.89MM.","DailyReturn":"-3.5%","FiveDayReturnAfter":"-4.94%","FiveDayReturnBefore":"1.75%"},{"Ticker":"IVZ","EffectiveDate":"2016-12-13","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods downgrades IVZ to Market Perform from Outperform.","DailyReturn":"-1.76%","FiveDayReturnAfter":"-2.85%","FiveDayReturnBefore":"1.84%"},{"Ticker":"IVZ","EffectiveDate":"2016-11-10","Type":"Dividend","Title":"The Firm pays dividend $0.28","DailyReturn":"3.99%","FiveDayReturnAfter":"6.39%","FiveDayReturnBefore":"8.38%"},{"Ticker":"IVZ","EffectiveDate":"2016-10-27","Type":"RevenueBeat","Title":"Before market open, IVZ reports 2016 Q3's earning $0.6 per share and revenue $854.7MM. This meets analyst's estimated EPS $0.6, misses estimated revenue $863.53MM.","DailyReturn":"-2.05%","FiveDayReturnAfter":"-7.07%","FiveDayReturnBefore":"-0.16%"},{"Ticker":"IVZ","EffectiveDate":"2016-10-14","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform.","DailyReturn":"-1.31%","FiveDayReturnAfter":"-1.62%","FiveDayReturnBefore":"-4.89%"},{"Ticker":"IVZ","EffectiveDate":"2016-10-14","Type":"RatingNeutral","Title":"Deutsche Bank downgrades IVZ to Hold from Buy.","DailyReturn":"-1.31%","FiveDayReturnAfter":"-1.62%","FiveDayReturnBefore":"-4.89%"},{"Ticker":"IVZ","EffectiveDate":"2016-10-13","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight.","DailyReturn":"-1.59%","FiveDayReturnAfter":"-3.46%","FiveDayReturnBefore":"-3.72%"},{"Ticker":"IVZ","EffectiveDate":"2016-10-11","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy.","DailyReturn":"-2.27%","FiveDayReturnAfter":"-5.52%","FiveDayReturnBefore":"-0.66%"},{"Ticker":"IVZ","EffectiveDate":"2016-10-05","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $36; previously $35.","DailyReturn":"1.84%","FiveDayReturnAfter":"-2.74%","FiveDayReturnBefore":"2.19%"},{"Ticker":"IVZ","EffectiveDate":"2016-10-04","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Neutral. Target Price is $33; previously $31.","DailyReturn":"-0.22%","FiveDayReturnAfter":"-0.66%","FiveDayReturnBefore":"3.82%"},{"Ticker":"IVZ","EffectiveDate":"2016-09-09","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $35; previously $34.","DailyReturn":"-2.25%","FiveDayReturnAfter":"-2.54%","FiveDayReturnBefore":"0.95%"},{"Ticker":"IVZ","EffectiveDate":"2016-08-16","Type":"Dividend","Title":"The Firm pays dividend $0.28","DailyReturn":"0.26%","FiveDayReturnAfter":"2.1%","FiveDayReturnBefore":"0.77%"},{"Ticker":"IVZ","EffectiveDate":"2016-08-09","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $36; previously $35.","DailyReturn":"-0.74%","FiveDayReturnAfter":"0.77%","FiveDayReturnBefore":"2.24%"},{"Ticker":"IVZ","EffectiveDate":"2016-08-05","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $33.","DailyReturn":"2.17%","FiveDayReturnAfter":"2.66%","FiveDayReturnBefore":"0%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $34.","DailyReturn":"0.89%","FiveDayReturnAfter":"0%","FiveDayReturnBefore":"2.84%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Neutral. Target Price is $31; previously $27.","DailyReturn":"0.89%","FiveDayReturnAfter":"0%","FiveDayReturnBefore":"2.84%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $34; previously $33.","DailyReturn":"0.89%","FiveDayReturnAfter":"0%","FiveDayReturnBefore":"2.84%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-29","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $37; previously $36.","DailyReturn":"0.89%","FiveDayReturnAfter":"0%","FiveDayReturnBefore":"2.84%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-28","Type":"EarningsRevenueBeat","Title":"Before market open, IVZ reports 2016 Q2's earning $0.56 per share and revenue $856.6MM. This beats analyst's estimated EPS $0.55, beats estimated revenue $848.82MM.","DailyReturn":"1.08%","FiveDayReturnAfter":"1.42%","FiveDayReturnBefore":"2.11%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-18","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $33; previously $32.","DailyReturn":"0.94%","FiveDayReturnAfter":"3.68%","FiveDayReturnBefore":"6.75%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-11","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $35.","DailyReturn":"0.74%","FiveDayReturnAfter":"6.75%","FiveDayReturnBefore":"0.35%"},{"Ticker":"IVZ","EffectiveDate":"2016-07-07","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $37.","DailyReturn":"0.68%","FiveDayReturnAfter":"6.54%","FiveDayReturnBefore":"4.08%"},{"Ticker":"IVZ","EffectiveDate":"2016-06-27","Type":"RatingNeutral","Title":"Citigroup downgrades IVZ to Neutral from Buy. Target Price is $27; previously $38.","DailyReturn":"-9.42%","FiveDayReturnAfter":"-0.94%","FiveDayReturnBefore":"-8.1%"},{"Ticker":"IVZ","EffectiveDate":"2016-06-16","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $35.","DailyReturn":"0.4%","FiveDayReturnAfter":"4.87%","FiveDayReturnBefore":"-7.68%"},{"Ticker":"IVZ","EffectiveDate":"2016-06-02","Type":"RatingNeutral","Title":"UBS downgrades IVZ to Neutral from Buy.","DailyReturn":"-1.53%","FiveDayReturnAfter":"-5.65%","FiveDayReturnBefore":"1.86%"},{"Ticker":"IVZ","EffectiveDate":"2016-05-11","Type":"Dividend","Title":"The Firm pays dividend $0.28","DailyReturn":"-2.22%","FiveDayReturnAfter":"-4.47%","FiveDayReturnBefore":"-0.46%"},{"Ticker":"IVZ","EffectiveDate":"2016-04-28","Type":"EarningsRevenueMiss","Title":"Before market open, IVZ reports 2016 Q1's earning $0.49 per share and revenue $818.1MM. This misses analyst's estimated EPS $0.54, misses estimated revenue $855.66MM.","DailyReturn":"-3.78%","FiveDayReturnAfter":"-9.64%","FiveDayReturnBefore":"1.07%"},{"Ticker":"IVZ","EffectiveDate":"2016-04-07","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $39; previously $36.","DailyReturn":"-3.77%","FiveDayReturnAfter":"1.48%","FiveDayReturnBefore":"-1.61%"},{"Ticker":"IVZ","EffectiveDate":"2016-04-05","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $36; previously $34.","DailyReturn":"-1.28%","FiveDayReturnAfter":"-4.84%","FiveDayReturnBefore":"1.94%"},{"Ticker":"IVZ","EffectiveDate":"2016-04-01","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $35; previously $32.","DailyReturn":"1.98%","FiveDayReturnAfter":"-3.87%","FiveDayReturnBefore":"1.2%"},{"Ticker":"IVZ","EffectiveDate":"2016-03-17","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $34; previously $33.","DailyReturn":"2.62%","FiveDayReturnAfter":"0.89%","FiveDayReturnBefore":"6.65%"},{"Ticker":"IVZ","EffectiveDate":"2016-02-16","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":"1.79%","FiveDayReturnAfter":"3.55%","FiveDayReturnBefore":"-2.16%"},{"Ticker":"IVZ","EffectiveDate":"2016-02-09","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $36; previously $39.","DailyReturn":"-0.5%","FiveDayReturnAfter":"4.53%","FiveDayReturnBefore":"-12.18%"},{"Ticker":"IVZ","EffectiveDate":"2016-02-09","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $32; previously $35.","DailyReturn":"-0.5%","FiveDayReturnAfter":"4.53%","FiveDayReturnBefore":"-12.18%"},{"Ticker":"IVZ","EffectiveDate":"2016-02-09","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $32; previously $34.","DailyReturn":"-0.5%","FiveDayReturnAfter":"4.53%","FiveDayReturnBefore":"-12.18%"},{"Ticker":"IVZ","EffectiveDate":"2016-01-19","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $33; previously $36.","DailyReturn":"0.2%","FiveDayReturnAfter":"-0.38%","FiveDayReturnBefore":"-4.65%"},{"Ticker":"IVZ","EffectiveDate":"2016-01-11","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $40; previously $41.","DailyReturn":"-0.66%","FiveDayReturnAfter":"-4.65%","FiveDayReturnBefore":"-10.54%"},{"Ticker":"IVZ","EffectiveDate":"2015-12-16","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $39; previously $43.","DailyReturn":"1.78%","FiveDayReturnAfter":"1.23%","FiveDayReturnBefore":"-4.7%"},{"Ticker":"IVZ","EffectiveDate":"2015-11-13","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":"-1.52%","FiveDayReturnAfter":"2.99%","FiveDayReturnBefore":"-4.24%"},{"Ticker":"IVZ","EffectiveDate":"2015-10-08","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $39; previously $41.","DailyReturn":"0.42%","FiveDayReturnAfter":"-5.86%","FiveDayReturnBefore":"5.51%"},{"Ticker":"IVZ","EffectiveDate":"2015-10-07","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $39; previously $46.","DailyReturn":"1.53%","FiveDayReturnAfter":"-3.25%","FiveDayReturnBefore":"5.3%"},{"Ticker":"IVZ","EffectiveDate":"2015-09-10","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $51.","DailyReturn":"0.64%","FiveDayReturnAfter":"3.56%","FiveDayReturnBefore":"-1.16%"},{"Ticker":"IVZ","EffectiveDate":"2015-09-08","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $40; previously $45.","DailyReturn":"3.03%","FiveDayReturnAfter":"2.19%","FiveDayReturnBefore":"-7.99%"},{"Ticker":"IVZ","EffectiveDate":"2015-09-03","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $43; previously $49.","DailyReturn":"-0.18%","FiveDayReturnAfter":"-0.66%","FiveDayReturnBefore":"-0.69%"},{"Ticker":"IVZ","EffectiveDate":"2015-09-03","Type":"RatingNeutral","Title":"Susquehanna maintains IVZ to Positive. Target Price is $39; previously $45.","DailyReturn":"-0.18%","FiveDayReturnAfter":"-0.66%","FiveDayReturnBefore":"-0.69%"},{"Ticker":"IVZ","EffectiveDate":"2015-08-18","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":"-0.45%","FiveDayReturnAfter":"-12.85%","FiveDayReturnBefore":"-3.16%"},{"Ticker":"IVZ","EffectiveDate":"2015-07-31","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $45; previously $44.","DailyReturn":"-1%","FiveDayReturnAfter":"-1%","FiveDayReturnBefore":"2.57%"},{"Ticker":"IVZ","EffectiveDate":"2015-07-20","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $43.","DailyReturn":"-0.38%","FiveDayReturnAfter":"-2.65%","FiveDayReturnBefore":"4.13%"},{"Ticker":"IVZ","EffectiveDate":"2015-07-14","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Neutral. Target Price is $46; previously $48.","DailyReturn":"1.36%","FiveDayReturnAfter":"2.24%","FiveDayReturnBefore":"0.61%"},{"Ticker":"IVZ","EffectiveDate":"2015-07-10","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $44; previously $47.","DailyReturn":"1.31%","FiveDayReturnAfter":"5.73%","FiveDayReturnBefore":"-3.66%"},{"Ticker":"IVZ","EffectiveDate":"2015-07-09","Type":"RatingNeutral","Title":"Susquehanna maintains IVZ to Positive. Target Price is $44; previously $48.","DailyReturn":"0.63%","FiveDayReturnAfter":"4.66%","FiveDayReturnBefore":"-3.44%"},{"Ticker":"IVZ","EffectiveDate":"2015-06-08","Type":"RatingNeutral","Title":"Goldman Sachs initiates coverage on IVZ to Neutral. Target Price is $44.","DailyReturn":"0.33%","FiveDayReturnAfter":"0.68%","FiveDayReturnBefore":"-1.59%"},{"Ticker":"IVZ","EffectiveDate":"2015-06-03","Type":"RatingNeutral","Title":"PiperJaffray initiates coverage on IVZ to Overweight. Target Price is $50.","DailyReturn":"-0.07%","FiveDayReturnAfter":"-2.18%","FiveDayReturnBefore":"-0.32%"},{"Ticker":"IVZ","EffectiveDate":"2015-05-13","Type":"Dividend","Title":"The Firm pays dividend $0.27","DailyReturn":"-0.61%","FiveDayReturnAfter":"-0.44%","FiveDayReturnBefore":"-0.7%"},{"Ticker":"IVZ","EffectiveDate":"2015-05-01","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $52; previously $51.","DailyReturn":"0.45%","FiveDayReturnAfter":"-0.99%","FiveDayReturnBefore":"1.48%"},{"Ticker":"IVZ","EffectiveDate":"2015-04-13","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $44.","DailyReturn":"0.67%","FiveDayReturnAfter":"-0.3%","FiveDayReturnBefore":"0.32%"},{"Ticker":"IVZ","EffectiveDate":"2015-04-10","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $47; previously $45.","DailyReturn":"-0.49%","FiveDayReturnAfter":"0.74%","FiveDayReturnBefore":"1.05%"},{"Ticker":"IVZ","EffectiveDate":"2015-04-08","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $51; previously $52.","DailyReturn":"0.7%","FiveDayReturnAfter":"1.34%","FiveDayReturnBefore":"-0.6%"},{"Ticker":"IVZ","EffectiveDate":"2015-04-02","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $45.","DailyReturn":"0.22%","FiveDayReturnAfter":"1.05%","FiveDayReturnBefore":"-0.75%"},{"Ticker":"IVZ","EffectiveDate":"2015-03-06","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $44.","DailyReturn":"-1.15%","FiveDayReturnAfter":"-0.04%","FiveDayReturnBefore":"0.69%"},{"Ticker":"IVZ","EffectiveDate":"2015-03-05","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Market Perform. Target Price is $52; previously $47.","DailyReturn":"0.66%","FiveDayReturnAfter":"-1.37%","FiveDayReturnBefore":"0.37%"},{"Ticker":"IVZ","EffectiveDate":"2015-03-05","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $46; previously $44.","DailyReturn":"0.66%","FiveDayReturnAfter":"-1.37%","FiveDayReturnBefore":"0.37%"},{"Ticker":"IVZ","EffectiveDate":"2015-02-17","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":"0.61%","FiveDayReturnAfter":"1.18%","FiveDayReturnBefore":"1.7%"},{"Ticker":"IVZ","EffectiveDate":"2015-01-30","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $50.","DailyReturn":"-2.75%","FiveDayReturnAfter":"3.02%","FiveDayReturnBefore":"1.19%"},{"Ticker":"IVZ","EffectiveDate":"2015-01-26","Type":"RatingUpgrade","Title":"Susquehanna upgrades IVZ to Positive from Neutral.","DailyReturn":"0.99%","FiveDayReturnAfter":"-0.81%","FiveDayReturnBefore":"3.01%"},{"Ticker":"IVZ","EffectiveDate":"2015-01-08","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $47; previously $48.","DailyReturn":"1.75%","FiveDayReturnAfter":"-3.09%","FiveDayReturnBefore":"-5.82%"},{"Ticker":"IVZ","EffectiveDate":"2015-01-07","Type":"RatingUpgrade","Title":"Sterne Agee upgrades IVZ to Buy from Neutral. Target Price is $47; previously $45.","DailyReturn":"1.31%","FiveDayReturnAfter":"0.32%","FiveDayReturnBefore":"-8.1%"},{"Ticker":"IVZ","EffectiveDate":"2015-01-06","Type":"RatingNeutral","Title":"Credit Suisse downgrades IVZ to Neutral from Outperform. Target Price is $45.","DailyReturn":"-2.07%","FiveDayReturnAfter":"-1.51%","FiveDayReturnBefore":"-5.92%"},{"Ticker":"IVZ","EffectiveDate":"2014-12-10","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $45; previously $44.","DailyReturn":"-2.02%","FiveDayReturnAfter":"-7.37%","FiveDayReturnBefore":"1.44%"},{"Ticker":"IVZ","EffectiveDate":"2014-12-09","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Market Perform. Target Price is $48; previously $45.","DailyReturn":"0.07%","FiveDayReturnAfter":"-6.23%","FiveDayReturnBefore":"1.89%"},{"Ticker":"IVZ","EffectiveDate":"2014-12-04","Type":"RatingNeutral","Title":"Barclays initiates coverage on IVZ to Overweight. Target Price is $45.","DailyReturn":"0.04%","FiveDayReturnAfter":"-0.44%","FiveDayReturnBefore":"0.02%"},{"Ticker":"IVZ","EffectiveDate":"2014-11-14","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":"-0.71%","FiveDayReturnAfter":"-1.34%","FiveDayReturnBefore":"-0.63%"},{"Ticker":"IVZ","EffectiveDate":"2014-10-14","Type":"RatingNeutral","Title":"Bank of America maintains IVZ to Buy. Target Price is $43; previously $45.","DailyReturn":"-0.91%","FiveDayReturnAfter":"1.75%","FiveDayReturnBefore":"-9.28%"},{"Ticker":"IVZ","EffectiveDate":"2014-10-14","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $44; previously $46.","DailyReturn":"-0.91%","FiveDayReturnAfter":"1.75%","FiveDayReturnBefore":"-9.28%"},{"Ticker":"IVZ","EffectiveDate":"2014-10-08","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $45; previously $46.","DailyReturn":"0.88%","FiveDayReturnAfter":"-7.62%","FiveDayReturnBefore":"-2.35%"},{"Ticker":"IVZ","EffectiveDate":"2014-09-11","Type":"RatingNeutral","Title":"Deutsche Bank maintains IVZ to Buy. Target Price is $45; previously $43.","DailyReturn":"0.64%","FiveDayReturnAfter":"0.93%","FiveDayReturnBefore":"-0.61%"},{"Ticker":"IVZ","EffectiveDate":"2014-08-19","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":"0.81%","FiveDayReturnAfter":"3.43%","FiveDayReturnBefore":"2.87%"},{"Ticker":"IVZ","EffectiveDate":"2014-08-08","Type":"RatingNeutral","Title":"Argus Research maintains IVZ to Buy. Target Price is $45; previously $42.","DailyReturn":"0.1%","FiveDayReturnAfter":"3.76%","FiveDayReturnBefore":"0.47%"},{"Ticker":"IVZ","EffectiveDate":"2014-08-01","Type":"RatingUpgrade","Title":"Deutsche Bank upgrades IVZ to Buy from Hold. Target Price is $43; previously $39.","DailyReturn":"0.5%","FiveDayReturnAfter":"0.47%","FiveDayReturnBefore":"-2.41%"},{"Ticker":"IVZ","EffectiveDate":"2014-08-01","Type":"RatingNeutral","Title":"UBS maintains IVZ to Neutral. Target Price is $40; previously $37.","DailyReturn":"0.5%","FiveDayReturnAfter":"0.47%","FiveDayReturnBefore":"-2.41%"},{"Ticker":"IVZ","EffectiveDate":"2014-08-01","Type":"RatingNeutral","Title":"Keefe Bruyette & Woods maintains IVZ to Outperform. Target Price is $46; previously $45.","DailyReturn":"0.5%","FiveDayReturnAfter":"0.47%","FiveDayReturnBefore":"-2.41%"},{"Ticker":"IVZ","EffectiveDate":"2014-07-08","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $44; previously $42.","DailyReturn":"-1.57%","FiveDayReturnAfter":"-1.56%","FiveDayReturnBefore":"2.51%"},{"Ticker":"IVZ","EffectiveDate":"2014-07-01","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $43; previously $42.","DailyReturn":"1.58%","FiveDayReturnAfter":"0.89%","FiveDayReturnBefore":"0.53%"},{"Ticker":"IVZ","EffectiveDate":"2014-07-01","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $44; previously $40.","DailyReturn":"1.58%","FiveDayReturnAfter":"0.89%","FiveDayReturnBefore":"0.53%"},{"Ticker":"IVZ","EffectiveDate":"2014-05-20","Type":"RatingUpgrade","Title":"JP Morgan upgrades IVZ to Overweight from Neutral. Target Price is $42; previously $41.","DailyReturn":"-0.51%","FiveDayReturnAfter":"2.61%","FiveDayReturnBefore":"-2.24%"},{"Ticker":"IVZ","EffectiveDate":"2014-05-16","Type":"RatingNeutral","Title":"Deutsche Bank initiates coverage on IVZ to Hold. Target Price is $39.","DailyReturn":"0.2%","FiveDayReturnAfter":"2.28%","FiveDayReturnBefore":"-1.87%"},{"Ticker":"IVZ","EffectiveDate":"2014-05-14","Type":"Dividend","Title":"The Firm pays dividend $0.25","DailyReturn":"-0.58%","FiveDayReturnAfter":"-2.4%","FiveDayReturnBefore":"2.18%"},{"Ticker":"IVZ","EffectiveDate":"2014-05-02","Type":"RatingNeutral","Title":"UBS maintains IVZ to Neutral. Target Price is $37; previously $36.","DailyReturn":"-0.16%","FiveDayReturnAfter":"-1.39%","FiveDayReturnBefore":"1.79%"},{"Ticker":"IVZ","EffectiveDate":"2014-05-02","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Neutral. Target Price is $41; previously $39.","DailyReturn":"-0.16%","FiveDayReturnAfter":"-1.39%","FiveDayReturnBefore":"1.79%"},{"Ticker":"IVZ","EffectiveDate":"2014-04-15","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Neutral. Target Price is $39; previously $38.","DailyReturn":"0.63%","FiveDayReturnAfter":"3.7%","FiveDayReturnBefore":"-0.63%"},{"Ticker":"IVZ","EffectiveDate":"2014-04-10","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $47; previously $48.","DailyReturn":"-2.33%","FiveDayReturnAfter":"-1.04%","FiveDayReturnBefore":"-5.81%"},{"Ticker":"IVZ","EffectiveDate":"2014-04-09","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $47; previously $48.","DailyReturn":"1.19%","FiveDayReturnAfter":"-1.43%","FiveDayReturnBefore":"-6.42%"},{"Ticker":"IVZ","EffectiveDate":"2014-02-18","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":"0.01%","FiveDayReturnAfter":"-0.89%","FiveDayReturnBefore":"4.4%"},{"Ticker":"IVZ","EffectiveDate":"2014-01-31","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $48; previously $44.","DailyReturn":"-0.74%","FiveDayReturnAfter":"-2.26%","FiveDayReturnBefore":"-4.35%"},{"Ticker":"IVZ","EffectiveDate":"2013-11-15","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":"-0.01%","FiveDayReturnAfter":"-0.19%","FiveDayReturnBefore":"5.11%"},{"Ticker":"IVZ","EffectiveDate":"2013-11-14","Type":"RatingUpgrade","Title":"Goldman Sachs upgrades IVZ to Buy from Neutral. Target Price is $38; previously $35.","DailyReturn":"2.37%","FiveDayReturnAfter":"1.26%","FiveDayReturnBefore":"0.66%"},{"Ticker":"IVZ","EffectiveDate":"2013-11-11","Type":"RatingUpgrade","Title":"Wells Fargo upgrades IVZ to Outperform from Market Perform.","DailyReturn":"0.75%","FiveDayReturnAfter":"2.21%","FiveDayReturnBefore":"-1.54%"},{"Ticker":"IVZ","EffectiveDate":"2013-10-31","Type":"EarningsBeatRevenueMiss","Title":"Before market open, IVZ reports 2013 Q3's earning $0.55 per share and revenue $816.4MM. This beats analyst's estimated EPS $0.52, misses estimated revenue $1170MM.","DailyReturn":"2.55%","FiveDayReturnAfter":"0.45%","FiveDayReturnBefore":"1.37%"},{"Ticker":"IVZ","EffectiveDate":"2013-10-16","Type":"RatingNeutral","Title":"JP Morgan downgrades IVZ to Neutral from Overweight. Target Price is $36; previously $41.","DailyReturn":"-1.07%","FiveDayReturnAfter":"0.24%","FiveDayReturnBefore":"2.87%"},{"Ticker":"IVZ","EffectiveDate":"2013-10-16","Type":"RatingNeutral","Title":"Sterne Agee initiates coverage on IVZ to Neutral. Target Price is $33.","DailyReturn":"-1.07%","FiveDayReturnAfter":"0.24%","FiveDayReturnBefore":"2.87%"},{"Ticker":"IVZ","EffectiveDate":"2013-08-19","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":"-1.93%","FiveDayReturnAfter":"-0.77%","FiveDayReturnBefore":"-1.64%"},{"Ticker":"IVZ","EffectiveDate":"2013-07-25","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $36; previously $38.","DailyReturn":"0.33%","FiveDayReturnAfter":"-1.54%","FiveDayReturnBefore":"2.69%"},{"Ticker":"IVZ","EffectiveDate":"2013-07-10","Type":"RatingNeutral","Title":"Evercore Partners initiates coverage on IVZ to Equal-Weight. Target Price is $35.","DailyReturn":"-2.21%","FiveDayReturnAfter":"-0.34%","FiveDayReturnBefore":"0.94%"},{"Ticker":"IVZ","EffectiveDate":"2013-06-17","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $39; previously $37.","DailyReturn":"2.47%","FiveDayReturnAfter":"-2.14%","FiveDayReturnBefore":"-2.7%"},{"Ticker":"IVZ","EffectiveDate":"2013-05-15","Type":"RatingNeutral","Title":"Barclays maintains IVZ to Overweight. Target Price is $38; previously $35.","DailyReturn":"1%","FiveDayReturnAfter":"0.53%","FiveDayReturnBefore":"5.57%"},{"Ticker":"IVZ","EffectiveDate":"2013-05-15","Type":"Dividend","Title":"The Firm pays dividend $0.225","DailyReturn":"1%","FiveDayReturnAfter":"0.53%","FiveDayReturnBefore":"5.57%"},{"Ticker":"IVZ","EffectiveDate":"2013-05-13","Type":"RatingNeutral","Title":"UBS downgrades IVZ to Neutral from Buy.","DailyReturn":"-0.2%","FiveDayReturnAfter":"2.05%","FiveDayReturnBefore":"4.95%"},{"Ticker":"IVZ","EffectiveDate":"2013-05-02","Type":"RatingUpgrade","Title":"Sterne Agee upgrades IVZ to Buy from Neutral. Target Price is $37; previously $33.","DailyReturn":"1.14%","FiveDayReturnAfter":"4.84%","FiveDayReturnBefore":"5.76%"},{"Ticker":"IVZ","EffectiveDate":"2013-05-01","Type":"RatingNeutral","Title":"Nomura maintains IVZ to Buy. Target Price is $35; previously $32.","DailyReturn":"-0.94%","FiveDayReturnAfter":"2.7%","FiveDayReturnBefore":"6.67%"},{"Ticker":"IVZ","EffectiveDate":"2013-04-30","Type":"EarningsRelease","Title":"Before market open, IVZ reports 2013 Q1's earning $0.52 per share and revenue $1142MM..","DailyReturn":"6.83%","FiveDayReturnAfter":"9.22%","FiveDayReturnBefore":"1.73%"},{"Ticker":"IVZ","EffectiveDate":"2013-04-23","Type":"RatingUpgrade","Title":"JP Morgan upgrades IVZ to Overweight from Neutral. Target Price is $34; previously $31.","DailyReturn":"1.67%","FiveDayReturnAfter":"1.73%","FiveDayReturnBefore":"0.85%"},{"Ticker":"IVZ","EffectiveDate":"2013-04-12","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $35; previously $34.","DailyReturn":"-0.16%","FiveDayReturnAfter":"-6.36%","FiveDayReturnBefore":"5.06%"},{"Ticker":"IVZ","EffectiveDate":"2013-04-05","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $33; previously $31.","DailyReturn":"-1.11%","FiveDayReturnAfter":"5.06%","FiveDayReturnBefore":"0.13%"},{"Ticker":"IVZ","EffectiveDate":"2013-04-05","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $33; previously $31.","DailyReturn":"-1.11%","FiveDayReturnAfter":"5.06%","FiveDayReturnBefore":"0.13%"},{"Ticker":"IVZ","EffectiveDate":"2013-03-01","Type":"RatingNeutral","Title":"Susquehanna initiates coverage on IVZ to Neutral. Target Price is $29.","DailyReturn":"0.14%","FiveDayReturnAfter":"4.2%","FiveDayReturnBefore":"1.84%"},{"Ticker":"IVZ","EffectiveDate":"2013-02-19","Type":"Dividend","Title":"The Firm pays dividend $0.172","DailyReturn":"1.73%","FiveDayReturnAfter":"-4.73%","FiveDayReturnBefore":"0.18%"},{"Ticker":"IVZ","EffectiveDate":"2013-02-05","Type":"RatingNeutral","Title":"BMO Capital downgrades IVZ to Market Perform from Outperform. Target Price is $29.","DailyReturn":"1.13%","FiveDayReturnAfter":"0.54%","FiveDayReturnBefore":"-2.56%"},{"Ticker":"IVZ","EffectiveDate":"2013-02-01","Type":"RatingNeutral","Title":"Stifel Nicolaus maintains IVZ to Buy. Target Price is $30; previously $29.","DailyReturn":"1.9%","FiveDayReturnAfter":"0.32%","FiveDayReturnBefore":"-1.89%"},{"Ticker":"IVZ","EffectiveDate":"2013-02-01","Type":"RatingNeutral","Title":"Morgan Stanley downgrades IVZ to Equal-Weight from Overweight. Target Price is $30.","DailyReturn":"1.9%","FiveDayReturnAfter":"0.32%","FiveDayReturnBefore":"-1.89%"},{"Ticker":"IVZ","EffectiveDate":"2013-01-31","Type":"EarningsRevenueMiss","Title":"Before market open, IVZ reports 2012 Q4's earning $0.45 per share and revenue $1090MM. This misses analyst's estimated EPS $0.47, misses estimated revenue $1110MM.","DailyReturn":"-3.64%","FiveDayReturnAfter":"-2.79%","FiveDayReturnBefore":"2.47%"},{"Ticker":"IVZ","EffectiveDate":"2013-01-14","Type":"RatingNeutral","Title":"JP Morgan downgrades IVZ to Neutral from Overweight. Target Price is $31; previously $32.","DailyReturn":"-1.44%","FiveDayReturnAfter":"-0.28%","FiveDayReturnBefore":"0.65%"},{"Ticker":"IVZ","EffectiveDate":"2012-11-15","Type":"Dividend","Title":"The Firm pays dividend $0.173","DailyReturn":"0.27%","FiveDayReturnAfter":"4.94%","FiveDayReturnBefore":"-2.45%"},{"Ticker":"IVZ","EffectiveDate":"2012-11-07","Type":"RatingNeutral","Title":"Bank of America assumes IVZ to Buy. Target Price is $30.","DailyReturn":"-3.12%","FiveDayReturnAfter":"-3%","FiveDayReturnBefore":"1.71%"},{"Ticker":"IVZ","EffectiveDate":"2012-11-02","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $27; previously $28.","DailyReturn":"-1.37%","FiveDayReturnAfter":"-4.08%","FiveDayReturnBefore":"2.78%"},{"Ticker":"IVZ","EffectiveDate":"2012-11-02","Type":"RatingNeutral","Title":"Nomura maintains IVZ to Buy. Target Price is $29; previously $28.","DailyReturn":"-1.37%","FiveDayReturnAfter":"-4.08%","FiveDayReturnBefore":"2.78%"},{"Ticker":"IVZ","EffectiveDate":"2012-11-01","Type":"EarningsRevenueMiss","Title":"IVZ reports 2012 Q3's earning $0.42 per share and revenue $1040MM. This misses analyst's estimated EPS $0.45, misses estimated revenue $1060MM.","DailyReturn":"1.72%","FiveDayReturnAfter":"-1.74%","FiveDayReturnBefore":"-0.85%"},{"Ticker":"IVZ","EffectiveDate":"2012-10-04","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $33; previously $27.5.","DailyReturn":"1.22%","FiveDayReturnAfter":"-1.58%","FiveDayReturnBefore":"3.08%"},{"Ticker":"IVZ","EffectiveDate":"2012-09-13","Type":"RatingNeutral","Title":"UBS maintains IVZ to Buy. Target Price is $29; previously $28.","DailyReturn":"2.68%","FiveDayReturnAfter":"2.37%","FiveDayReturnBefore":"4.62%"},{"Ticker":"IVZ","EffectiveDate":"2012-08-24","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $29; previously $28.","DailyReturn":"0.59%","FiveDayReturnAfter":"-0.72%","FiveDayReturnBefore":"-0.95%"},{"Ticker":"IVZ","EffectiveDate":"2012-08-20","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $27.5; previously $27.","DailyReturn":"-0.28%","FiveDayReturnAfter":"-0.28%","FiveDayReturnBefore":"1.42%"},{"Ticker":"IVZ","EffectiveDate":"2012-08-20","Type":"Dividend","Title":"The Firm pays dividend $0.173","DailyReturn":"-0.28%","FiveDayReturnAfter":"-0.28%","FiveDayReturnBefore":"1.42%"},{"Ticker":"IVZ","EffectiveDate":"2012-07-27","Type":"RatingNeutral","Title":"Morgan Stanley maintains IVZ to Overweight. Target Price is $29; previously $28.","DailyReturn":"5.78%","FiveDayReturnAfter":"3.75%","FiveDayReturnBefore":"-6.61%"},{"Ticker":"IVZ","EffectiveDate":"2012-07-27","Type":"RatingNeutral","Title":"BMO Capital maintains IVZ to Outperform. Target Price is $26; previously $27.","DailyReturn":"5.78%","FiveDayReturnAfter":"3.75%","FiveDayReturnBefore":"-6.61%"},{"Ticker":"IVZ","EffectiveDate":"2012-07-26","Type":"EarningsRevenueMiss","Title":"Before market open, IVZ reports 2012 Q2's earning $0.41 per share and revenue $1010MM. This misses analyst's estimated EPS $0.43, misses estimated revenue $1040MM.","DailyReturn":"2.04%","FiveDayReturnAfter":"6.65%","FiveDayReturnBefore":"-8.55%"},{"Ticker":"IVZ","EffectiveDate":"2012-07-16","Type":"RatingNeutral","Title":"JP Morgan maintains IVZ to Overweight. Target Price is $27; previously $28.","DailyReturn":"-2.38%","FiveDayReturnAfter":"-5.02%","FiveDayReturnBefore":"2.27%"},{"Ticker":"IVZ","EffectiveDate":"2012-07-10","Type":"RatingNeutral","Title":"Morgan Stanley maintains IVZ to Overweight. Target Price is $28; previously $29.","DailyReturn":"0.68%","FiveDayReturnAfter":"1.04%","FiveDayReturnBefore":"-3.23%"},{"Ticker":"IVZ","EffectiveDate":"2012-07-09","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $26; previously $30.","DailyReturn":"-1.17%","FiveDayReturnAfter":"2.27%","FiveDayReturnBefore":"1.5%"},{"Ticker":"IVZ","EffectiveDate":"2012-06-21","Type":"RatingNeutral","Title":"Argus Research initiates coverage on IVZ to Buy.","DailyReturn":"-3.06%","FiveDayReturnAfter":"-2.64%","FiveDayReturnBefore":"2.46%"},{"Ticker":"IVZ","EffectiveDate":"2012-05-18","Type":"RatingNeutral","Title":"UBS maintains IVZ to Buy. Target Price is $28; previously $29.","DailyReturn":"-2.22%","FiveDayReturnAfter":"-0.04%","FiveDayReturnBefore":"-4.32%"},{"Ticker":"IVZ","EffectiveDate":"2012-05-16","Type":"Dividend","Title":"The Firm pays dividend $0.173","DailyReturn":"-1.15%","FiveDayReturnAfter":"-4.38%","FiveDayReturnBefore":"-4.05%"},{"Ticker":"IVZ","EffectiveDate":"2012-05-10","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $28.5; previously $31.","DailyReturn":"-2.1%","FiveDayReturnAfter":"-4.39%","FiveDayReturnBefore":"-6.33%"},{"Ticker":"IVZ","EffectiveDate":"2012-04-27","Type":"RatingNeutral","Title":"Credit Suisse maintains IVZ to Outperform. Target Price is $32; previously $31.","DailyReturn":"0.15%","FiveDayReturnAfter":"-2.91%","FiveDayReturnBefore":"3.12%"},{"Ticker":"IVZ","EffectiveDate":"2012-04-26","Type":"EarningsRelease","Title":"Before market open, IVZ reports 2012 Q1's earning $0.43 per share and revenue $1033MM..","DailyReturn":"2.49%","FiveDayReturnAfter":"1.21%","FiveDayReturnBefore":"-0.2%"},{"Ticker":"IVZ","EffectiveDate":"2012-04-10","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $26.","DailyReturn":"-2.93%","FiveDayReturnAfter":"-2.04%","FiveDayReturnBefore":"-5.7%"},{"Ticker":"IVZ","EffectiveDate":"2012-04-09","Type":"RatingNeutral","Title":"Jefferies maintains IVZ to Buy. Target Price is $30; previously $26.","DailyReturn":"-3.18%","FiveDayReturnAfter":"-5.16%","FiveDayReturnBefore":"-0.42%"},{"Ticker":"IVZ","EffectiveDate":"2012-03-08","Type":"RatingNeutral","Title":"Citigroup maintains IVZ to Buy. Target Price is $30; previously $27.","DailyReturn":"1.4%","FiveDayReturnAfter":"6.81%","FiveDayReturnBefore":"-2.08%"},{"Ticker":"IVZ","EffectiveDate":"2012-02-21","Type":"Dividend","Title":"The Firm pays dividend $0.123","DailyReturn":"0.9%","FiveDayReturnAfter":"0.78%","FiveDayReturnBefore":"2.45%"},{"Ticker":"IVZ","EffectiveDate":"2012-02-21","Type":"RatingNeutral","Title":"UBS maintains IVZ to Buy. Target Price is $28; previously $25.","DailyReturn":"0.9%","FiveDayReturnAfter":"0.78%","FiveDayReturnBefore":"2.45%"}];